Community-acquired pneumonia. Diagnostic and therapeutic approach.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11190352.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Optimal empiric therapy of CAP is with appropriate monotherapy (e.g., doxycycline, levofloxacin). Combination therapy is problematic because of potential side effects and high cost. Empiric coverage should have a high degree of activity against both typical and atypical pathogens. The antibiotic selected should have an excellent side-effect profile and be relatively inexpensive. Clinicians should be selective in their choice of antibiotic for CAP and choose an antimicrobial that has little or no resistance potential, is relatively inexpensive, and permits i.v.-to-PO switch monotherapy.
Medical subject headings
- Anti-Bacterial Agents
- Community-Acquired Infections
- Drug Resistance, Multiple
- Pneumonia, Bacterial